Vimedimex Medi-Pharma JSC (HOSE:VMD)
Vietnam
· Delayed Price · Currency is VND 14,950
0.00 (0.00%)
At close: Apr 28, 2026
Vimedimex Medi-Pharma JSC Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 812,983 | 1,249,868 | 3,536,651 | 7,073,499 | 12,318,752 | Upgrade
|
| Revenue Growth (YoY) | -34.96% | -64.66% | -50.00% | -42.58% | -32.17% | Upgrade
|
| Cost of Revenue | 730,667 | 1,130,924 | 3,257,394 | 6,528,733 | 11,250,064 | Upgrade
|
| Gross Profit | 82,316 | 118,944 | 279,256 | 544,766 | 1,068,687 | Upgrade
|
| Selling, General & Admin | 39,599 | 113,447 | 244,237 | 512,617 | 915,955 | Upgrade
|
| Operating Expenses | 39,599 | 113,447 | 244,237 | 512,617 | 915,955 | Upgrade
|
| Operating Income | 42,716 | 5,497 | 35,019 | 32,149 | 152,733 | Upgrade
|
| Interest Expense | - | -3,703 | -1,749 | -5,107 | -15,745 | Upgrade
|
| Interest & Investment Income | 7,977 | 7,262 | 13,437 | 6,954 | 5,519 | Upgrade
|
| Currency Exchange Gain (Loss) | -3,020 | -6,562 | - | 12,540 | -115,776 | Upgrade
|
| Other Non Operating Income (Expenses) | 6,044 | 28,148 | -6,675 | 873.34 | 1,674 | Upgrade
|
| EBT Excluding Unusual Items | 53,718 | 30,643 | 40,031 | 47,410 | 28,404 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 29.09 | Upgrade
|
| Pretax Income | 53,718 | 30,643 | 40,031 | 47,410 | 28,433 | Upgrade
|
| Income Tax Expense | 11,290 | 7,090 | 11,768 | 12,256 | 9,084 | Upgrade
|
| Earnings From Continuing Operations | 42,427 | 23,553 | 28,263 | 35,154 | 19,349 | Upgrade
|
| Minority Interest in Earnings | -66.19 | -358.93 | -2,781 | -336.4 | 646.03 | Upgrade
|
| Net Income | 42,361 | 23,194 | 25,482 | 34,818 | 19,995 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | 1,178 | - | - | - | Upgrade
|
| Net Income to Common | 42,361 | 22,016 | 25,482 | 34,818 | 19,995 | Upgrade
|
| Net Income Growth | 82.64% | -8.98% | -26.81% | 74.13% | -46.10% | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Change (YoY) | - | -0.02% | 0.02% | - | - | Upgrade
|
| EPS (Basic) | 2743.54 | 1425.89 | 1650.00 | 2255.00 | 1295.00 | Upgrade
|
| EPS (Diluted) | 2743.54 | 1425.89 | 1650.00 | 2255.00 | 1295.00 | Upgrade
|
| EPS Growth | 92.41% | -13.58% | -26.83% | 74.13% | -46.10% | Upgrade
|
| Free Cash Flow | 10,565 | 111,673 | 5,543 | 696,919 | -442,484 | Upgrade
|
| Free Cash Flow Per Share | 684.23 | 7232.56 | 358.89 | 45136.46 | -28657.78 | Upgrade
|
| Gross Margin | 10.13% | 9.52% | 7.90% | 7.70% | 8.67% | Upgrade
|
| Operating Margin | 5.25% | 0.44% | 0.99% | 0.45% | 1.24% | Upgrade
|
| Profit Margin | 5.21% | 1.76% | 0.72% | 0.49% | 0.16% | Upgrade
|
| Free Cash Flow Margin | 1.30% | 8.94% | 0.16% | 9.85% | -3.59% | Upgrade
|
| EBITDA | 46,675 | 25,136 | 53,811 | 51,400 | 171,784 | Upgrade
|
| EBITDA Margin | 5.74% | 2.01% | 1.52% | 0.73% | 1.39% | Upgrade
|
| D&A For EBITDA | 3,958 | 19,638 | 18,792 | 19,251 | 19,051 | Upgrade
|
| EBIT | 42,716 | 5,497 | 35,019 | 32,149 | 152,733 | Upgrade
|
| EBIT Margin | 5.25% | 0.44% | 0.99% | 0.45% | 1.24% | Upgrade
|
| Effective Tax Rate | 21.02% | 23.14% | 29.40% | 25.85% | 31.95% | Upgrade
|
| Revenue as Reported | 812,983 | 1,249,868 | 3,536,651 | 7,073,499 | 12,318,752 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.